EA202090431A1 - INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT - Google Patents

INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT

Info

Publication number
EA202090431A1
EA202090431A1 EA202090431A EA202090431A EA202090431A1 EA 202090431 A1 EA202090431 A1 EA 202090431A1 EA 202090431 A EA202090431 A EA 202090431A EA 202090431 A EA202090431 A EA 202090431A EA 202090431 A1 EA202090431 A1 EA 202090431A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
muteins
interleukin
treatment
fusion proteins
Prior art date
Application number
EA202090431A
Other languages
Russian (ru)
Inventor
Халед М.К.З. Али
Нирадж Джагдиш Агравал
Гунасекаран Каннан
Ян ФОЛТЦ
Чжулунь Ван
Дарен Бейтс
Марисса Мок
Сунсеке Такенака
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Priority claimed from PCT/US2018/045105 external-priority patent/WO2019028316A1/en
Publication of EA202090431A1 publication Critical patent/EA202090431A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В изобретении предусмотрены мутеины IL-21 и слитые белки, содержащие их, для применения в способах лечения заболевания. Также в изобретении предусмотрены соответствующие конъюгаты, нуклеиновые кислоты, векторы, клетки-хозяева, фармацевтические композиции и наборы. В настоящем изобретении предусмотрены способы получения мутеинов IL-21 и слитых белков, содержащих их, а также способы лечения субъекта, нуждающегося в этом. Дополнительно предусмотрены антигенсвязывающие белки для PD-1.The invention provides IL-21 muteins and fusion proteins containing them for use in methods of treating disease. Also provided by the invention are appropriate conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions, and kits. The present invention provides methods for producing IL-21 muteins and fusion proteins containing them, as well as methods for treating a subject in need thereof. Additionally, antigen binding proteins for PD-1 are provided.

EA202090431A 2018-01-12 2018-08-03 INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT EA202090431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616733P 2018-01-12 2018-01-12
PCT/US2018/045105 WO2019028316A1 (en) 2017-08-03 2018-08-03 Interleukin-21 muteins and methods of treatment

Publications (1)

Publication Number Publication Date
EA202090431A1 true EA202090431A1 (en) 2021-03-16

Family

ID=71842940

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090431A EA202090431A1 (en) 2018-01-12 2018-08-03 INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT

Country Status (2)

Country Link
AR (1) AR114079A1 (en)
EA (1) EA202090431A1 (en)

Also Published As

Publication number Publication date
AR114079A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
CY1125429T1 (en) INTERLEUKIN-21 MUTEINS AND METHODS OF THERAPEUTIC TREATMENT
EA202091710A1 (en) ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE
UY38049A (en) ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS
CO2018012415A2 (en) Specific binding proteins and uses thereof
CY1119647T1 (en) ALUMINUM ACCESSORIES AND ACCESSORIES FOR ACCESSORIES
CY1119219T1 (en) ANTI-CEACAM5 ANTIBODIES AND THEIR USES
EA201991383A1 (en) ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
EA201892616A1 (en) ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
PE20200148A1 (en) ANTI-TREM2 ANTIBODIES AND METHODS TO USE THEM
EA202092735A1 (en) ANTAGONIZING CD73 ANTIBODY
EA201590138A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND THE ACTIVATION GENE OF LYMPHOCYTES 3 (LAG-3) AND THEIR USE
EA201991763A1 (en) CCR7 ANTIBODY AND MEDICINE CONJUGATES
EA201892774A1 (en) ANTIBODIES
EP4339615A3 (en) Anti-pd-1 antibodies
CY1122436T1 (en) ANTIBODIES AGAINST THE EPITANIAL GROWTH FACTOR RECEPTOR (EGFR)
EA202092459A1 (en) INTERLEUKIN 12 HYBRID PROTEINS, COMPOSITIONS AND METHODS OF THERAPEUTIC APPLICATION, WHICH INCLUDE THEM
EA202090372A1 (en) UNIVERSAL AVT CONNECTIONS AND THEIR APPLICATION
EA202090387A1 (en) PROTEINS BINDING NKG2D, CD16 AND FLT3
EA202190468A1 (en) MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16 AND METHODS OF THEIR APPLICATION
EA201790489A1 (en) THERAPEUTIC TOOLS BASED ON ANTIBODIES, BINDING OprF AND OprI
MX2021011330A (en) Claudin-6 antibodies and drug conjugates.
EA202192488A1 (en) ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS
EA202191658A1 (en) ANTIBODIES AGAINST HUMAN COMPLETE FACTOR C2B AND METHODS OF APPLICATION
EA202090431A1 (en) INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT
EA202091596A1 (en) ANTIBODIES TO PD-1 AND METHODS OF TREATMENT